top of page

The Science Behind the News: Ascidian Therapeutics' IND is cleared for an RNA exon editing program against Stargardt disease

blonca9
Jan 29, 2024
1 min read

Ascidian Interim President & CEO Mike Ehlers explains the scientific concept of RNA exon editing, how Stargardt as an indication is a natural fit as a proof of concept, and why he believes FDA clearance of the IND without ex-U.S. clinical data is meaningful.

Recent Posts

Bay Area based Nosis Bio is leveraging AI to get its gene silencers specifically to precise cell types - it recently announced a development candidate to tackle fibrosis

Bay Area based Nosis Bio is leveraging AI to get its gene silencers specifically to precise cell types - it recently announced a development candidate to tackle fibrosis

Checking in with Alector CEO Arnon Rosenthal ahead of a pivotal trial readout for latozinemab in frontotemporal dementia in the fourth quarter

Checking in with Alector CEO Arnon Rosenthal ahead of a pivotal trial readout for latozinemab in frontotemporal dementia in the fourth quarter

IDEAYA Biosciences is at the forefront of precision oncology - we discuss the pipeline, including a key pivotal trial that will read out for Darovasertib by the end of the year

IDEAYA Biosciences is at the forefront of precision oncology - we discuss the pipeline, including a key pivotal trial that will read out for Darovasertib by the end of the year

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.

Learn more about Genezen

bottom of page